Does Presbyterian Healthcare Services Cover Prolia?

What Prolia Is and Why Coverage Decisions Matter

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK-L (receptor activator of nuclear factor kappa-B ligand), a protein that drives osteoclast formation. By blocking RANK-L, denosumab slows bone resorption, raises bone mineral density, and reduces fracture rates. The FDA approved denosumab 60 mg for postmenopausal osteoporosis in June 2010, making it one of the most studied anti-resorptive agents available.

Coverage decisions matter because the list price for a single 60 mg prefilled syringe runs roughly $2,100. Two injections per year equals about $4,200 annually before any discounts. For patients on fixed incomes, that figure is simply not manageable without insurance coverage.

How Denosumab Differs From Bisphosphonates

Bisphosphonates such as alendronate are taken daily or weekly as oral tablets and cost a few dollars per month as generics. Denosumab is a biologic given by a clinician every six months. That difference in delivery means denosumab is generally billed as a medical benefit (Part B for Medicare patients) rather than a pharmacy benefit (Part D), which changes how Presbyterian Healthcare Services processes the claim entirely.

FDA-Approved Indications That Drive Coverage Eligibility

PHS, like most insurers, ties coverage to FDA-approved indications. Those currently include:

• Postmenopausal women with osteoporosis at high risk for fracture
• Men with osteoporosis at high risk for fracture
• Women receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high fracture risk
• Men receiving androgen deprivation therapy for nonmetastatic prostate cancer who are at high fracture risk
• Glucocorticoid-induced osteoporosis in adults who are initiating or continuing systemic glucocorticoids at a daily dose equivalent to 7.5 mg or more of prednisone for at least 6 months

If your diagnosis falls outside these categories, PHS may deny the claim on the basis of "not medically necessary." Your prescriber can request an off-label exception, but success rates vary.

Presbyterian Healthcare Services Coverage Framework for Prolia

Presbyterian Healthcare Services is a New Mexico-based nonprofit integrated health system offering commercial HMO and PPO plans, Medicaid managed care (Centennial Care), and Medicare Advantage products. The exact coverage rules differ across product lines, but the underlying clinical criteria are similar.

Commercial HMO and PPO Plans

For members on commercial PHS plans, Prolia typically sits on Specialty Tier (Tier 4 or Tier 5) of the pharmacy formulary when dispensed through a specialty pharmacy. When administered in a physician's office or infusion center, it is processed under the medical benefit instead.

Prior authorization is almost universally required. Standard documentation includes:

• A current DEXA scan showing T-score <-2.5 at the spine or hip, OR a T-score <-1.0 with a prior fragility fracture
• A FRAX score (10-year major osteoporotic fracture risk) of 20% or higher, OR hip fracture risk of 3% or higher, consistent with National Osteoporosis Foundation / American College of Rheumatology guidance
• Documentation that the patient has tried and failed, or has a contraindication to, an oral bisphosphonate such as alendronate or risedronate

That last requirement is the one most often overlooked. PHS and similar plans use step therapy protocols that position bisphosphonates as first-line agents because they are cheaper. Step therapy policies in osteoporosis management are common across U.S. Payers and can delay access to denosumab by months if the prescriber does not document bisphosphonate failure or intolerance upfront.

Medicare Advantage Plans Offered by Presbyterian

PHS operates Medicare Advantage plans in New Mexico. For these members, the billing pathway is different. Denosumab 60 mg administered in a physician's office is billed under Medicare Part B using HCPCS code J0897. Medicare Part B covers 80% of the allowed amount after the annual deductible is met. The PHS Medicare Advantage plan then covers most or all of the remaining 20%, depending on the specific plan design.

CMS National Coverage Determination (NCD) 150.3 covers bone density studies that document eligibility, and the DEXA scan itself is covered under Part B every 24 months for qualifying beneficiaries, or more frequently if medically necessary. Your provider needs that DEXA result in the chart before submitting the Prolia prior authorization.

Centennial Care (New Mexico Medicaid) Administered by PHS

For PHS Centennial Care members, denosumab coverage follows the New Mexico Human Services Department's Medicaid preferred drug list. Bisphosphonate step therapy requirements typically apply here as well. Centennial Care generally does not charge cost-sharing for covered drugs to members below certain income thresholds, so the out-of-pocket burden can be lower than on commercial plans if authorization is granted.

Clinical Evidence Supporting Prolia Coverage Approval

Insurers use published clinical evidence when writing their coverage criteria. Understanding that evidence helps patients and prescribers make stronger authorization arguments.

The FREEDOM Trial: Landmark Fracture Reduction Data

The phase 3 FREEDOM trial (N=7,808 postmenopausal women with osteoporosis, T-score <-2.5 to >-4.0) showed that denosumab 60 mg every 6 months over 36 months reduced new vertebral fractures by 68% (relative risk reduction), hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo. These results were published in the New England Journal of Medicine in 2009. The FREEDOM extension, following patients for up to 10 years, confirmed sustained BMD gains with no evidence of a fracture rebound during continued treatment.

That 68% reduction in vertebral fractures is the number your prescriber should cite in the prior authorization letter. It is the strongest single efficacy data point and directly mirrors the language most payer coverage policies use.

DEXA Scan Thresholds and FRAX Scores

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines define "high fracture risk" as a T-score <-2.5 with no prior fracture, or "very high risk" as a T-score <-3.0 or a prior fragility fracture. AACE explicitly lists denosumab as an appropriate first-line agent for very high-risk patients, which gives clinicians a guideline-based argument to skip bisphosphonate step therapy in those cases.

Provide the AACE risk classification language directly in the prior authorization form. Many PHS reviewers will accept documented "very high risk" classification as sufficient justification to bypass the bisphosphonate step.

Secondary Osteoporosis and Special Populations

Patients on long-term glucocorticoids deserve special attention. A 2018 randomized controlled trial published in the New England Journal of Medicine (N=795) showed that denosumab was superior to risedronate in increasing lumbar spine BMD in patients receiving glucocorticoids, with no significant difference in adverse events. This trial directly supported the FDA's 2018 label expansion to glucocorticoid-induced osteoporosis, which in turn strengthens coverage arguments for this indication with PHS.

How to Get Prior Authorization Approved

The single biggest reason Prolia prior authorizations fail is incomplete documentation. The checklist below addresses the most common deficiencies.

Documents Your Provider Should Submit

1. Completed PHS prior authorization form for specialty biologics (available through the PHS provider portal or by calling PHS provider services).
2. DEXA scan report with T-scores at the lumbar spine and total hip, dated within 24 months.
3. FRAX calculation printout from shef.ac.uk/FRAX showing 10-year fracture probability.
4. Bisphosphonate trial documentation or letter of contraindication (e.g., esophageal disease, renal impairment with GFR <35 mL/min, documented intolerance).
5. Diagnosis codes ICD-10 M81.0 (age-related osteoporosis without pathological fracture) or M80.x (with fracture), plus any secondary codes for glucocorticoid use (Z79.52) if applicable.
6. Letter of medical necessity from the prescribing physician citing the FREEDOM trial data, the AACE risk classification, and the specific clinical factors that make denosumab appropriate for this patient.

Typical PHS Prior Authorization Timeline

PHS is required under New Mexico state law and CMS rules to process standard prior authorization requests within 3 business days for non-urgent cases and 72 hours (or faster) for urgent cases. If you have not received a decision in that window, call PHS member services and ask for a status update by reference number.

What Happens If PHS Denies the Request

A denial is not the end of the road. PHS must provide a written denial with the specific clinical reason. Common denial reasons include:

• "Step therapy not completed" (bisphosphonate not tried)
• "Insufficient documentation of osteoporosis diagnosis"
• "Not medically necessary based on current BMD"

Each denial can be appealed. The first level is an internal appeal reviewed by a PHS medical director. If that fails, New Mexico members have the right to request an independent external review through the New Mexico Office of Superintendent of Insurance. For Medicare Advantage members, the appeal pathway follows CMS Medicare Advantage grievance and appeal rules, which include up to five levels of appeal culminating in federal district court review.

The HealthRX Prior Authorization Success Framework for Prolia identifies three documents that, when submitted together on the initial request, raise first-pass approval rates: (1) the DEXA scan report with T-score, (2) a FRAX printout exceeding the 20%/3% threshold, and (3) a physician letter explicitly citing AACE "very high risk" classification. Plans that receive all three together are far less likely to issue a bisphosphonate step-therapy denial.

Cost Assistance Programs When Coverage Falls Short

Even with PHS coverage, cost-sharing can be a barrier. Several programs address this.

Amgen ASSIST Program

Amgen operates the Prolia ASSIST program, which offers:

• A copay card for commercially insured patients that can reduce out-of-pocket cost to $0 per dose (income and eligibility restrictions apply)
• Free product through the Amgen Safety Net Foundation for uninsured or underinsured patients who meet income criteria (generally at or below 500% of the federal poverty level)

Medicare patients are not eligible for the commercial copay card due to federal anti-kickback rules, but they may qualify for the Safety Net Foundation program.

Medicare Extra Help / Low-Income Subsidy

For PHS Medicare Advantage members with low incomes, the Medicare Extra Help program (Low-Income Subsidy) can reduce Part D cost-sharing. Because Prolia is typically Part B when administered in-office, Extra Help does not directly apply to the injection itself, but it may reduce costs for associated medications.

New Mexico Medicaid Expansion

New Mexico expanded Medicaid under the Affordable Care Act. Adults with incomes up to 138% of the federal poverty level qualify for Centennial Care through PHS. If a patient currently paying commercial insurance premiums qualifies for Centennial Care, switching plans could eliminate Prolia cost-sharing entirely, assuming authorization is approved.

Monitoring Requirements and Ongoing Coverage Renewal

Getting the first authorization approved is only half the job. PHS will require reauthorization, typically every 12 months, to confirm that Prolia is still clinically appropriate.

Labs and Monitoring PHS May Require

Before each reauthorization cycle, have the following documented in the chart:

• Serum calcium (hypocalcemia is a contraindication; baseline and ongoing monitoring is required per FDA prescribing information)
• Serum creatinine and estimated GFR (severe renal impairment increases hypocalcemia risk)
• Repeat DEXA scan (every 1 to 2 years per AACE guidelines) to document treatment response
• Dental exam documentation (osteonecrosis of the jaw is a rare but serious adverse event; PHS may require documented dental clearance before continued therapy)

Discontinuation Risk: Rebound Vertebral Fractures

One piece of clinical information that patients and prescribers must understand before starting Prolia: stopping denosumab abruptly causes rapid bone loss and a significant increase in vertebral fracture risk within 12 to 18 months after the last dose. A 2017 study in Osteoporosis International (N=1,001) documented multiple vertebral fractures occurring after denosumab discontinuation. If PHS coverage lapses or is denied at renewal, the prescriber should immediately initiate transition therapy with a bisphosphonate to preserve bone density. This is not optional. It is a patient safety issue.

Comparing Prolia to Covered Alternatives

If PHS ultimately denies Prolia coverage after appeals, alternatives with potentially easier coverage pathways include:

| Agent | Route | Frequency | Typical Tier | |---|---|---|---| | Alendronate (generic) | Oral | Weekly | Tier 1 generic | | Risedronate (generic) | Oral | Weekly or monthly | Tier 1-2 generic | | Zoledronic acid (generic Reclast) | IV infusion | Yearly | Medical benefit | | Raloxifene (generic Evista) | Oral | Daily | Tier 2-3 | | Romosozumab (Evenity) | SC injection | Monthly x 12 | Specialty tier | | Teriparatide (Forteo/generic) | SC injection | Daily x 24 months | Specialty tier |

Zoledronic acid 5 mg IV once yearly is often the most accessible alternative when denosumab is denied. A 2007 NEJM trial (HORIZON-PFT, N=7,736) showed a 70% reduction in vertebral fractures and a 41% reduction in hip fractures over 3 years, making its efficacy profile comparable to denosumab. It is billed under the medical benefit like Prolia, requires a single annual infusion, and is available as a generic, which significantly lowers the authorization barrier.

For patients at very high fracture risk, particularly those with T-scores below -3.0 or a recent hip fracture, 2023 AACE guidance recommends anabolic therapy with romosozumab or teriparatide before switching to an anti-resorptive. This anabolic-first strategy has a growing evidence base and may itself require a separate prior authorization battle with PHS.

What Prescribers Should Know About the PHS Provider Portal

PHS requires most specialty drug prior authorizations to be submitted through their provider portal or through CoverMyMeds, an electronic prior authorization platform integrated with many EHR systems. Submitting on paper by fax significantly slows turnaround. Practices that use CoverMyMeds can track authorization status in real time and receive electronic notifications when additional information is requested.

CoverMyMeds processing data shows that electronic prior authorizations are completed on average 7 days faster than fax submissions. For a patient in pain or at imminent fracture risk, that week matters.

PHS provider services can be reached at the number listed on the back of the member's insurance card. The provider relations line (separate from member services) handles authorization disputes and peer-to-peer review requests. A peer-to-peer call between the prescribing physician and the PHS medical director is one of the most effective tools for overturning a denial.

Special Circumstances That Affect Coverage

Cancer-Related Bone Loss

Women receiving aromatase inhibitors for breast cancer and men receiving androgen deprivation therapy for prostate cancer both experience accelerated bone loss. Denosumab at the 60 mg dose is FDA-approved for fracture risk reduction in both groups. Endocrine Society guidelines recommend assessing BMD in all patients starting these therapies, and PHS commercial plans typically cover Prolia for this indication with documentation of BMD decline or high baseline fracture risk.

Patients With Renal Impairment

Oral bisphosphonates are contraindicated when estimated GFR falls below 35 mL/min. This contraindication gives prescribers a clear, documented reason to skip bisphosphonate step therapy and go directly to denosumab. Include the most recent creatinine lab value and calculated GFR in the prior authorization submission. PHS reviewers are trained to recognize this contraindication and generally approve requests that document it.

Male Osteoporosis

Osteoporosis in men is underdiagnosed and often undercovered. PHS commercial plans cover Prolia for male osteoporosis, but the prior authorization criteria mirror those for women. A DEXA scan with T-score <-2.5 and documentation of high fracture risk or bisphosphonate failure is still required. The Endocrine Society's 2012 clinical practice guideline on male osteoporosis supports pharmacologic treatment for men with T-scores <-2.5 or prior fragility fractures, and citing this guideline in the authorization letter strengthens the case.